翰宇药业股票讨论区

Despite Hybio Pharmaceutical's recent poor growth, its high P/S ratio indicates investor optimism for a business turnaround. However, with medium-term revenue decline and expected industry growth of 35%, these prices may not be sustainable. Shareholders may face a tough period unless circumstances improve.

Hybio Pharmaceutical's falling revenue and pre-tax losses pose concerns over its debt level, implying potential threat to the company while its shares seem unaffected. It's deemed risky due to these factors.